Form 4: Krystal Biotech Director Christopher Mason Awarded Stock Options

Director Christopher Mason of Krystal Biotech, Inc. was granted stock options to purchase 5,000 shares of common stock on June 30, 2024.

Summary

• Christopher Mason, a director at Krystal Biotech, Inc., received stock options on June 30, 2024.
• The options grant the right to purchase 5,000 shares of Krystal Biotech's common stock at an exercise price of $183.64 per share.
• The options vest in equal monthly installments over a one-year period.
• The options expire on June 30, 2034.

Sentiment

Score: 7

Explanation: The document itself is neutral, simply reporting a stock option grant. However, the granting of options to a director is generally viewed positively as it aligns interests with shareholders and incentivizes performance.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and contribution to the company over the next year.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance, but the granting of stock options suggests an expectation of future growth and value creation.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to incentivize performance and align management's interests with those of shareholders. This grant is consistent with industry practices for compensating directors.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded biotech companies.
• The size of the grant (5,000 shares) and the vesting schedule (monthly over one year) are within typical ranges for director compensation in companies of Krystal Biotech's size and stage of development.
• Comparable companies like CRISPR Therapeutics or Editas Medicine also utilize stock options as part of their director compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with theirs.
• Employees may see this as a sign of confidence in the company's future prospects.

Key Dates